Swiss Pharmaceuticals & Biotech Potentially Undervalued Companies

Cosmo Pharmaceuticals

Market Cap: CHF 891.0m

Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.

Teva Pharmaceutical Industries

Market Cap: CHF 18.6b

Develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.

Novartis

Market Cap: CHF 190.8b

Engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally.

Johnson & Johnson

Market Cap: CHF 420.1b

Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.

Bayer

Market Cap: CHF 19.3b

Operates as a life science company worldwide.

Bristol-Myers Squibb

Market Cap: CHF 100.3b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

Novartis

Market Cap: CHF 190.8b

Engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally.

Merck

Market Cap: CHF 206.7b

Operates as a healthcare company worldwide.

Jazz Pharmaceuticals

Market Cap: CHF 7.0b

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.

BioMarin Pharmaceutical

Market Cap: CHF 11.2b

A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.

Merck KGaA

Market Cap: CHF 48.2b

Operates as a science and technology company in Germany.

Gilead Sciences

Market Cap: CHF 94.1b

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Qiagen

Market Cap: CHF 9.2b

Provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.

Roche Holding

Market Cap: CHF 214.6b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.

Gerresheimer

Market Cap: CHF 1.5b

Provides medicine packaging, drug delivery devices, and solutions in Germany and internationally.

Roche Holding

Market Cap: CHF 214.6b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.

Evotec

Market Cap: CHF 1.9b

Operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally.

Biogen

Market Cap: CHF 27.0b

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

Eli Lilly

Market Cap: CHF 592.9b

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.

Siegfried Holding

Market Cap: CHF 3.8b

Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.

AstraZeneca

Market Cap: CHF 179.7b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

Tilray Brands

Market Cap: CHF 1.4b

A lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally.

Newron Pharmaceuticals

Market Cap: CHF 150.7m

A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.

Relief Therapeutics Holding

Market Cap: CHF 34.5m

A biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases.

Tecan Group

Market Cap: CHF 2.1b

Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.

SKAN Group

Market Cap: CHF 1.5b

Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.

CRISPR Therapeutics

Market Cap: CHF 5.3b

A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

BioNTech

Market Cap: CHF 27.1b

A biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.

Amgen

Market Cap: CHF 145.8b

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Siegfried Holding

Market Cap: CHF 3.9b

Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.

UCB

Market Cap: CHF 16.3b

A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.

Moderna

Market Cap: CHF 53.4b

A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.

Basilea Pharmaceutica

Market Cap: CHF 634.3m

Engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections.

Joincare Pharmaceutical Group IndustryLtd

Market Cap: US$22.5b

Joincare Pharmaceutical Group Industry Co.,Ltd.

Idorsia

Market Cap: CHF 526.5m

A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, and Canada.

Santhera Pharmaceuticals Holding

Market Cap: CHF 174.3m

A specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.